Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis

INTRODUCTION: Tildrakizumab is a humanized IgG1κ monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved in 2018 for the treatment of patients with moderate-to-severe chronic plaque psoriasis. OBJECTIVES: This study aimed to evaluate the effectiveness, safety and survival of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Brizzi, Eugenia Veronica, Buononato, Dario, Benvenuto, Pierfrancesco, Argenziano, Giuseppe, De Pasquale, Rocco, Fiorella, Carmen Silvia, Giofrè, Claudia, Musumeci, Maria Letizia, Palazzo, Giovanni, Zichichi, Leonardo, Balato, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656146/
https://www.ncbi.nlm.nih.gov/pubmed/37992389
http://dx.doi.org/10.5826/dpc.1304a215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656146/
https://www.ncbi.nlm.nih.gov/pubmed/37992389
http://dx.doi.org/10.5826/dpc.1304a215

Ejemplares similares